TY - JOUR
T1 - Therapy-Related Acute Myeloid Leukemia With t(8;21) (q22;q22) Shares Many Features With De Novo Acute Myeloid Leukemia With t(8;21)(q22;q22) but Does Not Have a Favorable Outcome
AU - Gustafson, Steven A.
AU - Lin, Pei
AU - Chen, Su S.
AU - Chen, Lei
AU - Abruzzo, Lynne V.
AU - Luthra, Rajyalakshmi
AU - Medeiros, L. Jeffrey
AU - Wang, Sa A.
PY - 2009/5
Y1 - 2009/5
N2 - To determine if therapy-related acute myeloid leukemia (t-AML) with t(8;21)(q22;q22) [t-AML-t(8;21)] harbors similar characteristic clinicopathologic features as de novo AML-t(8;21) (q22;q22), we studied 13 cases of t-AML-t(8;21) and 38 adult cases of de novo AML-t(8;21) diagnosed and treated at our hospital (1995-2008). Of 13 t-AML-t(8;21) cases, 11 had previously received chemotherapy with or without radiation for malignant neoplasms and 2 received radiation alone. The median latency to t-AML onset was 37 months (range, 11-126 months). Compared with patients with de novo AML-t(8;21), patients with t-AML-t(8;21) were older (p =.001) and had a lower WBC count (P =.039), substantial morphologic dysplasia, and comparable CD19/CD56 expression. The AML1-ETO (RUNX1- RUNX1T1) fusion was demonstrated in all 10 cases assessed. Class I mutations analyzed included FLT3 (0/10 [0%]), RAS (0/10 [0%]), JAK2 V617 (0/11 [0%]), and KIT (4/11 [36%]). With a median follow-up of 13 months, 10 patients with t-AML-t(8;21) died; the overall survival was significantly inferior to that of patients with de novo AML-t(8;21) (19 months vs not reached; P =. 002). These findings suggest that t-AML-t(8;21) shares many features with de novo AML-t(8;21)(q22;q22), but affected patients have a worse outcome.
AB - To determine if therapy-related acute myeloid leukemia (t-AML) with t(8;21)(q22;q22) [t-AML-t(8;21)] harbors similar characteristic clinicopathologic features as de novo AML-t(8;21) (q22;q22), we studied 13 cases of t-AML-t(8;21) and 38 adult cases of de novo AML-t(8;21) diagnosed and treated at our hospital (1995-2008). Of 13 t-AML-t(8;21) cases, 11 had previously received chemotherapy with or without radiation for malignant neoplasms and 2 received radiation alone. The median latency to t-AML onset was 37 months (range, 11-126 months). Compared with patients with de novo AML-t(8;21), patients with t-AML-t(8;21) were older (p =.001) and had a lower WBC count (P =.039), substantial morphologic dysplasia, and comparable CD19/CD56 expression. The AML1-ETO (RUNX1- RUNX1T1) fusion was demonstrated in all 10 cases assessed. Class I mutations analyzed included FLT3 (0/10 [0%]), RAS (0/10 [0%]), JAK2 V617 (0/11 [0%]), and KIT (4/11 [36%]). With a median follow-up of 13 months, 10 patients with t-AML-t(8;21) died; the overall survival was significantly inferior to that of patients with de novo AML-t(8;21) (19 months vs not reached; P =. 002). These findings suggest that t-AML-t(8;21) shares many features with de novo AML-t(8;21)(q22;q22), but affected patients have a worse outcome.
KW - Mutation
KW - Survival
KW - T(8;21)(q22;q22)
KW - Therapy-related acute myeloid leukemia
UR - http://www.scopus.com/inward/record.url?scp=65349103909&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=65349103909&partnerID=8YFLogxK
U2 - 10.1309/AJCP5ETHDXO6NCGZ
DO - 10.1309/AJCP5ETHDXO6NCGZ
M3 - Article
C2 - 19369623
AN - SCOPUS:65349103909
SN - 0002-9173
VL - 131
SP - 647
EP - 655
JO - American journal of clinical pathology
JF - American journal of clinical pathology
IS - 5
ER -